Combination therapies: The next logical Step for the treatment of synucleinopathies?
- 21 September 2015
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 31 (2), 225-234
- https://doi.org/10.1002/mds.26428
Abstract
Currently there are no disease‐modifying alternatives for the treatment of most neurodegenerative disorders. The available therapies for diseases such as Parkinson's disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), in which the protein alpha‐synuclein (α‐Syn) accumulates within neurons and glial cells with toxic consequences, are focused on managing the disease symptoms. However, using strategic drug combinations and/or multi‐target drugs might increase the treatment efficiency when compared with monotherapies. Synucleinopathies are complex disorders that progress through several stages, and toxic α‐Syn aggregates exhibit prion‐like behavior spreading from cell to cell. Therefore, it follows that these neurodegenerative disorders might require equally complex therapeutic approaches to obtain significant and long‐lasting results. Hypothetically, therapies aimed at reducing α‐Syn accumulation and cell‐to‐cell transfer, such as immunotherapy against α‐Syn, could be combined with agents that reduce neuroinflammation with potential synergistic outcomes. Here we review the current evidence supporting this type of approach, suggesting that such rational therapy combinations, together with the use of multi‐target drugs, may hold promise as the next logical step for the treatment of synucleinopathies. © 2015 International Parkinson and Movement Disorder SocietyFunding Information
- National Institutes of Health (NS044233, AG18440, NS047303, AG022074)
This publication has 150 references indexed in Scilit:
- Efficient Gene Therapy for Parkinson's Disease Using Astrocytes as Hosts for Localized Neurotrophic Factor DeliveryMolecular Therapy, 2012
- C-reactive protein is related to memory and medial temporal brain volume in older adultsBrain, Behavior, and Immunity, 2012
- Translation Initiator EIF4G1 Mutations in Familial Parkinson DiseaseAmerican Journal of Human Genetics, 2011
- A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson DiseaseAmerican Journal of Human Genetics, 2011
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Mechanisms Underlying Inflammation in NeurodegenerationCell, 2010
- Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cellsCellular Immunology, 2009
- Repression of α-synuclein expression and toxicity by microRNA-7Proceedings of the National Academy of Sciences of the United States of America, 2009
- Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2Biochemical and Biophysical Research Communications, 2009
- Cathepsin D Is the Main Lysosomal Enzyme Involved in the Degradation of α-Synuclein and Generation of Its Carboxy-Terminally Truncated SpeciesBiochemistry, 2008